Abstract: An electrical connector of the present invention comprises an insulative housing, a plurality of grounding contacts and a plurality of shells. Each contact comprises an engaging portion forming an S-shaped spring arm punched out of a plane thereof and bent backward and extending in a longitudinal direction. The spring arm of the contact resiliently interferingly fits with a distal end of a retention tab of the shell, in such manner that the grounding contacts can easily connect with shells to produce effective shielding.

Abstract: An electrical connector of the present invention comprises an insulative housing, a front shell, a pair of locking posts and a pair of integral-formed boardlocks. The insulative housing defines a pair of receiving recesses for engaging with the pair of boardlocks. Each receiving recess comprises a first slot and a second slot separated by a retaining body formed by the housing in the receiving recess. The pair of boardlocks each comprise a body section defining a screw portion used to function as a nut, a resilient section received in the first slot and abutting a rearward surface of a front wall of the housing, which is used to function as a washer, and a board-locking section retained in the second slot. Thus the boardlocks are adapted for simplifying the manufacture and assembly thereof and reducing the cost of production, compared with the prior art.

Abstract: Depot drug formulations include the pharmaceutical itself and a three component release rate controlling matrix composition. The three components of the matrix composition are (1) a pH dependent gelling polymer such as an alginate component, (2) an enteric polymer component, such as Eudragit.RTM. L or S, and (3) a pH independent gelling polymer, such as hydroxy propyl methyl cellulose or polyethylene oxide. The drug release rate can be adjusted by changing the amount of one or more of these components of the composition.

Abstract: Verapamil depot drug formulations include the pharmaceutical itself and a three component release rate controlling matrix composition. The three components of the matrix composition are (1) an alginate component, such as sodium alginate, (2) an enteric polymer component, such as methacrylic acid copolymer, and (3) a pH independent gelling polymer, such as hydroxypropyl methylcellulose or polyethyleneoxide. The drug release rate can be adjusted by changing the amount of one or more of these components of the composition.

Abstract: The subject invention is a process to manufacture a sustained release pharmaceutical tablet. The process includes granulation of inactive ingredients, such as hydroxypropyl cellulose, with active ingredients, such as nifedipine; followed by micronization of the granules. Additional granulation of further active or inactive ingredients is done with or without the micronized granules formed in the first step. All of the granules are then dried if necessary, lubricated, and compressed into tablets which slowly release the active ingredient over a controlled length of time.